FIELD: pharmaceuticals.
SUBSTANCE: pharmaceutical compositions containing a GLP-1 peptide and an N-(8-(2-hydroxybenzoyl)amino)caprylic acid salt.
EFFECT: method for treating diabetes mellitus and/or obesity in a subject.
10 cl, 4 ex, 8 tbl, 2 dwg
Title | Year | Author | Number |
---|---|---|---|
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
SOLID COMPOSITIONS CONTAINING AGONIST TO GLP AND SALT OF N-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | 2011 |
|
RU2600440C2 |
GLP-1 PEPTIDES COMPOSITIONS AND THEIR PRODUCTION | 2013 |
|
RU2641198C2 |
ORAL DOSING OF GLUCAGON-LIKE PEPTIDE-1 COMPOUNDS | 2014 |
|
RU2671406C2 |
SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
ACYLATED GLP-1 COMPOUNDS | 2006 |
|
RU2434019C2 |
DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
Authors
Dates
2023-11-10—Published
2019-02-01—Filed